Abstract. COVID-19 has swept through mainland China by human-to-human transmission. The rapid spread of SARS-CoV-2 and its variants, including the currently prevalent Omicron strain, pose a serious threat worldwide. The present review summarizes epidemiological investigation and etiological analysis of genomic, epidemiological, and pathological characteristics of the original strain and its variants, as well as progress in diagnosis and treatment. Prevention and control measures used during the current Omicron pandemic are discussed to provide further knowledge of SARS-CoV-2.

Contents
1. Introduction
2. Epidemiological features
3. Clinical and pathological manifestation
4. Diagnosis
5. Treatment
6. Measures to protect vulnerable groups: Vaccination
7. Conclusion

1. Introduction
COVID-19, caused by novel coronavirus SARS-CoV-2, has posed a serious threat to human health and public safety globally with rapid transmission and serious pathogenicity (1). Novel variants of the original virus are emerging on a frequent basis. Omicron strain has rapid speed of transmission and has replaced Delta strain as the most prevalent currently, causing large scale global infection, it was first discovered in Johannesburg, South Africa, then identified in Belgium, Israel, Hong Kong and European countries (2). The Omicron cases in South Africa peaked at 40,000 per day (Dec 2021), while UK had >100,000 cases per day (Dec 2021), with Omicron accounting for 90% of all patients with COVID-19 in London (3,4). Omicron has been identified in >100 countries and has caused >1 million daily cases up to 3rd June, 2022 (2).

SARS-CoV-2, a single-stranded RNA β-coronavirus genus, is enveloped by membrane with polymorphic shape, commonly round or oval (5). Glycoproteins on the membrane surface include spike (S) protein, which serves as a receptor-binding and antigenic sites that trigger cytolysis by inducing antigenic response (6); small envelope (E) glycoprotein, which mediates binding to the envelope; membrane (M) glycoprotein, which is responsible for nutrient transmembrane transport, budding release of virus and formation of virus envelope and nucleocapsid (N) protein, which can be used as a diagnostic antigen and encapsulates the viral genome (7). As heavily glycosylated S trimers, S proteins bind to the human angiotensin converting enzyme 2 receptor (ACE2) and mediate viral entry into target human cells, making S protein the most important in the pathogenesis of infection (8). SARS-CoV-2 infects humans by binding to ACE2, which is the same host receptor for SARS-CoV. SARS-CoV-2 binds ACE2 of respiratory epithelial cells before multiplying, passing through the airways and finally entering alveolar epithelial cells (9). Massive viral duplication in the lung triggers the immune response, which causes aggregation and accumulation of inflammatory cells, resulting in typical symptoms of viral pneumonia (10). Acute pulmonary infection can cause complications, the most severe of which are acute respiratory distress syndrome (ARDS) and respiratory failure, which have become the leading cause of death during the epidemic (11,12). A cohort study of 459
intensive care units from 50 countries and 5 continents found that the mortality rate is 26.0–61.5% for patients with ARDS who received critical care and 65.7–94.0% for patients who received mechanical ventilation (12).

Similar to other viruses, the novel coronavirus genome exhibits variations that may alter its biological features. Changes in the affinity of S protein and ACE-2 may affect viral invasion of cells, replication and transmission, production of antibodies during recovery or following vaccination, the neutralization activity of antibody may be impaired (13). Delta variant (B.1.617.2) exhibits 23 mutations compared with the original strain, 12 of which are in the novel S protein (14). The increased number of mutated S proteins make immune recognition and antibodies attachment more difficult, leading to a higher infection rate in human cells (15). The newly reported Omicron strain exhibits a considerable number of mutations in S protein as well. Among 50 mutations, 23 of them are in the S protein, preventing antibodies from attaching to S protein, resulting in increased transmissibility and infectivity (16).

2. Epidemiological features

SARS-CoV-2 appears to be particularly infectious in crowded places with poor ventilation and the chance of infection following exposure to SARS-CoV-2 is similar between different age groups (17), while people appear to develop a degree of immunity following vaccination or infection.

Compared with the original strain, variants exhibit similar epidemiological features. Although there is no conclusive evidence that Delta variant causes distinct symptoms from Alpha, patients infected by Delta variant exhibit more rapid onset and higher viral expression in the respiratory tract (18). It is hypothesized that the infectiousness of Delta variant is double that of the original strain, indicating a higher potential infection and death rate (19). Omicron variant is notably more contagious compared with Delta as a result of its mutations on the S protein receptor-binding domain (RBD) (20). Patients infected with Omicron variant often present with mild symptoms and severe symptoms are rare (21). In terms of age, it has a greater impact on young and middle-aged people than previous variants (22). Omicron also exhibits greater ability to escape from antibodies, which can lead to more cases of reinfection and infection following vaccination (20).

During outbreaks, however, clinical features differ between age groups. According to a study (23), the incidence of pre-existing comorbidities such as hypertension, diabetes and cardiovascular disorder is higher among the elderly (age, ≥60 years), who may have more underlying disease and be in poorer physical condition compared with young and middle-aged groups. Regarding pulmonary infection and comorbidities, elderly patients have a higher risk of severe respiratory disease requiring intensive care (24), while younger patients may only exhibit moderate pneumonia, asymptomatic infection or be less likely to develop COVID-19 (23). Additionally, studies have indicated that immunocompromised hosts, such as patients with HIV or active cancer or receiving high-dose steroid therapy, may be more likely to develop complications following infection with SARS-CoV-2 (25,26).

Infected people are the primary source of infection, as well as asymptomatic patients and patients in latent period (27). It is hypothesized that transmission via aerosols is the primary route from infected patients to non-infected people (28). Patients in latent period without symptoms also discharge virus particles into the environment at similar levels to symptomatic patients, which poses a threat to public safety (29).

Droplets are the primary infective agents of SARS-CoV-2. When a patient breathes, coughs or sneezes, respiratory droplets with high viral load are expelled from the mouth and nose (30). Infected people produce an aerosol form of SARS-CoV-2 as particles (diameter, <5 μm) suspended in gas (31). However, the likelihood of infection depends on the distance between the source and the susceptible person (32). Short-distance airborne transmission, including via droplet and aerosol, which is also known as ‘direct contact’, may serve as the principal pathway of virus dissemination (33). On the other hand, ‘indirect contact’ occurs when pathogens exhaled by carriers of SARS-CoV-2 contaminate objects and infect susceptible individuals exposed to them (34).

Epidemiological analysis and pathogenesis indicate the respiratory tract is the primary route of infection (35). ACE2+ cells in the respiratory tract are viral receptors and may be responsible to human-to-human transmission (36). Droplets and aerosol carrying the virus enter the respiratory tract of susceptible person, typically in the form of saliva, sputum and nasal secretion, and begin to multiply by binding ACE2 (Fig. 1) (37). Other routes of transmission such as fecal-oral, mother-to-child and body fluid transmission are controversial and lack direct, real-word evidence. Nosocomial infection is a key route of virus transmission. Samples of item surfaces and air from confirmed patient wards were tested positive, implying that SARS-CoV-2 can spread in examination rooms and wards (38), which indicates the necessity of guarding against infection during clinical activity requiring open mouth and contact with body fluids, such as endoscopy, dental treatment and pulmonary function test (39).

3. Clinical and pathological manifestation

Based on an epidemiological survey, the incubation period for COVID-19 is 1-14 days, with the majority of cases lasting 3-7 days (40). Fever, dry cough and exhaustion are reported as the three most prevalent symptoms, while certain patients exhibit expectoration, nasal obstruction, runny nose, sore throat, emaciation, hemoptysis, headache, chest pain, chills, myalgia, gastrointestinal responses and olfactory and taste disorder (41,42). Vaccinated people or those infected with Omicron generally present with asymptomatic infection or mild symptoms, while symptomatic patients primarily manifest with upper respiratory infection (43). Dyspnea and hypoxemia are the main manifestations of severely ill patients and typically develop within one week of symptomatic presentation (30). Severely ill patients rapidly develop ARDS, septic shock, coagulopathy, refractory metabolic acidosis and multiple organ failure. Certain patients develop central nervous symptom disorder and acral ischemic necrosis of the extremities (1). Severely or critically ill patients may present with moderate to low fever, while mild patients present with slight weariness, odor and taste disturbance, as well as low fever, but
no visible signs or symptoms of pneumonia (44). According to a study in China, mild cases form the majority of total cases, while severe cases requiring intensive care and critical cases with life-threatening emergency complications represented <20% of the study population (45). As aforementioned, the risk level of COVID-19 varies by age. In addition, age and male are risk factors for cardiovascular disease, therefore, elderly men infected by SARS-CoV-2 may have a higher risk of developing severe cases with respiratory and circulatory failure, while the young and middle-aged people may be able to recover in two weeks (44).

In the early phase of COVID-19, peripheral blood displays lymphopenia and decreased or normal leukocyte count, while certain patients present with high levels of aspartate aminotransferase, lactate dehydrogenase, myoglobin, creatine kinase, troponin and ferritin. In terms of inflammatory indicators, C-reactive protein and erythrocyte sedimentation are increased in the majority of patients (9). Increased expression of D-dimer and decreased peripheral lymphocyte levels may present in severe cases with respiratory and circulatory failure, while the young and middle-aged people may be able to recover in two weeks (44).

In the early phase of COVID-19, peripheral blood displays lymphopenia and decreased or normal leukocyte count, while certain patients present with high levels of aspartate aminotransferase, lactate dehydrogenase, myoglobin, creatine kinase, troponin and ferritin. In terms of inflammatory indicators, C-reactive protein and erythrocyte sedimentation are increased in the majority of patients (9). Increased expression of D-dimer and decreased peripheral lymphocyte levels may present in severe cases (46). Hypercytokinemia, characterized by high expression of cytokines in plasma, is common in severely and critically ill patients, potentially resulting in death within 16 days of disease onset (47).

Computerized tomography (CT) scanning of the patient chest commonly reveals bilateral patchy shadow or ground-glass opacity with subpleural, centrilobular and diffused distribution (48). The tiny shadows rapidly expand into a scattered distribution as the disease progresses. Organizing pneumonia and fibrosis are primarily observed in the later stages of COVID-19 without pleural effusion (49).

Histological examination shows bilateral diffuse alveolar injury with mucinous exudation of cellular fibers, desquamation of pneumocytes and fibrin deposits and hyaline membrane formation, which indicate the occurrence of ARDS (50). In the course of COVID-19, inflammatory infiltration of mononuclear cells, primarily lymphocytes, occurs in alveoli, which indicates that directional aggregation of lymphocytes may lead to peripheral lymphopenia. Alveolar cells exhibit large nuclei, double cytoplasmic granules and obvious nucleoli, indicating cytotoxic alteration, which is also observed in other organs, such as spleen, hilar lymph node, bone marrow, heart and blood vessels, liver, gallbladder, kidney, adrenal gland, alimentary epithelial cells, brain and testicles (51).

Nucleic acid detection is primarily used for etiological examination. By serological examination, specific IgM induced by SARS-CoV-2 infection can be detected; positive results of IgG antibody may be seen within the first week of onset (52).

A cohort study of patients recovering from COVID-19 reported symptoms including weariness, muscle discomfort, sleeping difficulty and psychological problems such as anxiety or depression 6 months after the onset of COVID-19. Severely ill patients exhibited more obvious symptoms following recovery; in addition to impaired pulmonary diffusion function and damaged (as revealed by chest imaging), cardiovascular, nervous, digestive, urinary and immune symptoms were observed (53,54). Therefore, recovery following COVID-19 still requires long-term epidemiological investigation.
4. Diagnosis

During the Omicron epidemic, RT-qPCR nucleic acid detection was used as the gold standard for diagnosis of COVID-19 (55). For unvaccinated patients, detection of specific antibodies such as IgM and IgG are used as a diagnostic reference. However, for those who have been vaccinated or have a history of previous infection, these antibodies may not have diagnostic value (56).

Omicron appears to cause more asymptomatic cases and patients with mild symptoms or in the incubation period can lead to wide and undetected viral spread (57). Therefore, early identification and close monitoring of suspected cases are key for public protection against Omicron. Based on current studies (55,57), symptoms caused by SARS-CoV-2 variants vary between infected individuals, which yields limitations in common detection methods. Therefore, absence of respiratory symptoms and pulmonary inflammation or negative PCR test do not mean the patient is non-infectious, indicating that early recognition is critical during clinical tests (58). Diagnostic techniques must be updated to be more sensitive and adaptable to emergence of novel variants.

RT-qPCR is used for rapid detection of SARS-CoV-2. Compared with next-generation gene sequencing (NGS), it is faster and cheaper, provides clear results and has a larger sample capacity (59). Lower respiratory tract samples exhibit higher viral load compared with samples from other sources, with oral and nasopharyngeal swabs being more convenient and commonly used (60). Negative RT-qPCR results from respiratory samples have been obtained while positive results were obtained from intestinal canal and peripheral blood (61), indicating that isolation of live viruses is key to assess virus reproduction (62). The outcome of RT-qPCR nucleic acid detection tends to be inadequate due to complicating factors (57). False negative results can be due to virus mutations that make primers and probes difficult to recognize, low viral load in samples caused by viral mutations or non-standard sampling, different detection reagents and poor quality control (63,64). Therefore, screening hospital patients via RT-qPCR may be insufficient and multiple approaches are needed for confirmation of the novel coronavirus. Specific primers targeting key mutations in S protein rapidly recognize variants of concern that may differ from previous Omicron mutations (65). Metagenomic NGS should also be used to analyze nucleic acid, especially for patients who may be infected with a SARS-CoV-19 variant (66). Loop-mediated isothermal amplification, which is highly specific for mutations, detection with 6-8 specific primer sequences, may be substitute for a RT-qPCR diagnosis (67). Contact tracing is required to avoid the omission of potential transmitters and help to cut off the transmission route.

Serology can be used for diagnosis along with RT-qPCR. Antibody-based techniques are not recommended for early detection owing to the long period for inducing antibody responses, while antigen-based immunoassays such as ELISA assess immune response and disease progression by detecting N or S protein on antibodies (68). However, serology cannot exclude the effects of cross-reactivity caused by factors such as muramidase, rheumatoid factors and heterophile antibodies (69). The intensity and duration of immune responses may differ between individuals and disease stage and serological tests exhibit varying sensitivity and specificity, creating obstacles to their application, while biosensor technologies may improve the specificity and sensitivity of diagnosis (70).

Chest X-ray or CT imaging are also used as diagnostic techniques for the novel coronavirus (71). Bilateral ground-glass opacity is indicative of SARS-CoV-2. The sensitivity of chest CT has been proven as it accurately diagnoses infection in the presence of negative RT-qPCR results (72). Therefore, chest CT combined with repeated RT-qPCR may be a reliable technique for suspected cases with negative initial RT-qPCR detection (73). However, improper technique and atypical manifestation can result in false negatives (71).

Recently, artificial intelligence (AI) as an emerging technology for interpreting chest imaging and quick diagnosis of COVID-19 has been widely discussed (74-76). AI applications are used in imaging platforms, region segmentation for lung infection, clinical assessment and auxiliary diagnosis based on meta-analysis (74). Based on its operational principles of interpreting chest imaging and quick diagnosis (77), it may also contribute to clinical and basic research associated with SARS-CoV-2, in addition to assisting diagnosis in clinical practice. Accurately distinguishing COVID-19 from other respiratory disease improves the efficiency of diagnoses and simplifies workflow, which primarily depends on manual work of radiologists, providing more accurate results and maintaining safety of medical staff during examination (75). At this stage, AI diagnosis still needs to improve image acquisition and expand sample capacity, which is the foundation of segmentation and diagnosis (76). For physicians, AI results of chest imaging must be considered in light of clinical manifestation and laboratory examination (78).

5. Treatment

Currently, numerous specific targeted medicines have passed phase III clinical trials and proven to have therapeutic efficacy against COVID-19, despite preliminary or controversial results of clinical trials. Existing antiviral drugs and their combination are recommended, while extensive tests are needed to demonstrate the effectiveness and pharmacokinetic and safety profiles of specific targeted drugs before widespread use as a therapy for COVID-19 (Table I) (79).

Antiviral medicines for SARS-CoV-2 can be divided into two groups based on the molecular mechanism: Drugs targeting viral protein or RNA and drugs targeting host protein or biological processes that allow viral entry into cells (80). Antiviral therapies should be used in the early stage of disease, especially for patients with higher risk of developing severe illness, as early intervention is more effective compared with treatment in severe cases (81).

Interferon, which confers congenital immunity to viruses, induce the expression of antiviral proteins (AVPs) such as 2′-5′A synthase and protein kinase to impede viral replication (82). Interferon-α has been demonstrated by studies to be effective against SARS-CoV and may be more sensitive against SARS-CoV-2 (83). COVID-19 guidelines in China recommend interferon-α as an antiviral drug (84). Interferon-β has proven useful in certain trials (85,86) but further studies are needed to evaluate its effectiveness in high-risk cases.
### Table I. Antiviral and antibody-based therapy for COVID-19.

#### A. Antiviral therapy

| Name                          | Company                  | Indication                                                                 | Mechanism of action                                                                 | Effectiveness                                                                 |
|-------------------------------|--------------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Interferon-α, Interferon-β    | Multiple                 | Viral infection and certain types of malignant tumors                       | Protects lower airway                                                                | No obvious therapeutic effect on hospitalized patients with COVID-19 |
| Interferon-γ                  | Eiger Biopharmaceuticals | Early phase of mild COVID-19                                                | Protects upper and lower airway continuously, inhibits cytokine storm                 | Risk reduction of hospitalizations or ER visits, 50% (trial no. NCT04967430) |
| Lopinavir                     | Multiple                 | HIV-1 infection                                                             | Inhibits HIV-1 3CLpro                                                                | Lopinavir + ritonavir has no obvious therapeutic effect on hospitalized patients with COVID-19 (trial no. CTR20002930) |
| Ritonavir                     | Multiple                 | HIV-1 and HIV-2 infection                                                   | Inhibits CYP3A4 activity, decreases metabolism of antiviral agents                   |                                                                              |
| GC-376                        | N/A                      | Feline infectious peritonitis COVID-19                                       | Inhibits SARS-CoV-2 3CLpro                                                          | Potential                                                                    |
| PF-07304814, PF-07321332      | Pfizer                   | Patients with mild-to-moderate COVID-19 (adults and children aged >12 years) with high risk of transforming into severe cases | Nirmatrevir inhibits SARS-COV-2 3CLpro, ritonavir serves as an adjuvant              | Risk reduction of hospitalization or ER visit, 89% (trial no. NCT04960202) |
| Umifenovir (Arbidol)          | BHBT                     | Influenza                                                                   | Targets interaction between influenza virus S protein and ACE2 of host cells, induces interferon | Potential (trial no. IRCT20180725040596N2)                                  |
| Gelactoferrin                 | N/A                      | Acute symptoms of chronic pancreatitis                                      | Inhibits TMRSS2 and protease, trypsin and matriptase activity                        | Potential                                                                    |
| Camostat mesylate             | N/A                      | Ebola and Marburg virus, patients with mild-to-moderate COVID-19 (adults and young children aged >28 days and weighing ≥3 kg) | Inhibits expression of viral RNA polymerase                                           | Requires verification. (trial no. NCT04257656.)                               |
| Remdesivir (GS-5734)          | Gilead Sciences, Inc.    | Influenza, RNA virus infection                                              | Inhibits expression of viral RNA polymerase                                          |                                                                              |
| Favilavir/ Favipiravir (T-705) | FUJIFILM Wako Pure Chemical Corporation |                                                                              | Requires verification.                                                              |                                                                              |
### A. Antiviral therapy

| Name | Company | Indication | Mechanism of action | Effectiveness | (Refs.) |
|------|---------|------------|---------------------|---------------|---------|
| Molnupiravir (MK-4482/ EIDD-2801) | MSD, Ridgeback Biotherapeutics LP | Patients with mild-to-moderate COVID-19 (adults) | Inhibits expression of viral RNA polymerase | Risk reduction of hospitalization or death, 50%, (trial no. NCT04575597) | (108) |
| Bemfinosbuvir (AT-527) | Roche, Atea Pharmaceuticals | Patients with mild-to-moderate COVID-19 not requiring hospitalization | Inhibits expression of viral RNA polymerase | Requires verification. Did not meet primary clinical endpoint (trial no. NCT04709835) | (109) |
| Merimepodib (VX-497) | N/A | RNA virus infection | Inhibits IMPDH, suppresses replication of RNA virus | Potential | (200) |
| Plitidepsin | PharmaMar | Multiple myeloma | Inhibits eEF1A | Potential | (110) |
| Fluvoxamine | Multiple | Depression, mild COVID-19 | Inhibits selective serotonin reuptake | Requires verification (trial no. NCT04342663) | (114) |
| Chloroquine, hydroxychloroquine | N/A | Malaria and rheumatoid arthritis | Inhibit TLRs | Potential but with obvious side effects | (96) |

### B. Antibody-based therapy

| Name | Company | Indication | Mechanism of action | Effectiveness | (Refs.) |
|------|---------|------------|---------------------|---------------|---------|
| Convalescent plasma | N/A | Patients with COVID-19 with high risk factors, rapid progression or severe or critical COVID-19 | Purified neutralizing antibody against SARS-COV-2 obtained from recovered COVID-19 patients | Potential but controversial | (201) |
| Polyclonal antibody | N/A | Transplantation reaction, autoimmune disease | Immunizing animals with antigen containing multiple epitopes stimulates multiple B cell clones to produce antibodies against multiple epitopes | Potential | (202) |
| Miniprotein | N/A | | Artificially designed, high affinity binding to RBD of SARS-CoV-2 S protein | Potential | (203) |
| Nanobody | N/A | | Alpaca-derived antibodies, bind to RBD of SARS-CoV-2 S protein, prevent ACE2 binding | Potential | (204) |
| Tocilizumab (Actemra) | Roche | Rheumatoid arthritis, severe or critically | Monoclonal antibody, binds to non-signaling | Effective but controversial | (205) |
Table I. Continued.

B. Antibody-based therapy

| Name                      | Company                        | Indication                                                                 | Mechanism of action                              | Effectiveness                                                                 | (Refs.)                  |
|---------------------------|--------------------------------|----------------------------------------------------------------------------|--------------------------------------------------|-------------------------------------------------------------------------------|--------------------------|
| Sarilumab (Kevzara)       | Sanofi S.A.                    | ill patients with COVID-19                                                 | site of IL-6 (CD126)                              | (trial no. NCT04356937)^a                                                   | (132)                    |
|                           | Regeneron Pharmaceuticals, Inc. | Rheumatoid arthritis, severe or critically ill patients with COVID-19     | Monoclonal antibody, targets α subunit of IL-6 receptor complex | Effective but controversial                                                 |                          |
| Sotrovimab (VIR-7831)     | GlaxoSmithKline, Vir Biotechnology, Inc. | Patients with mild-to-moderate COVID-19 (age, >12 years) with high risk of severe illness or hospitalization | Monoclonal antibody, binds to highly conserved epitope of SARS-CoV-2 S protein | Potential but controversial                                                   | (206)                    |
|                           | Regeneron Pharmaceuticals, Inc. | Monoclonal antibody, inhibits VEGF to suppress growth of new blood vessels | (trial no. NCT04545060)^a                          |                                                                               |                          |
| Bevacizumab (Avastin)      | Roche                          | Metastatic cancer, severe or critically ill patients with COVID-19         | Monoclonal antibody, binds to RBD of SARS-CoV-2 S protein | Risk reduction of hospitalization or death, 70%                              | (133)                    |
| Bamlanivimab + Etesevimab | Eli Lilly and Company, Top Alliance Biosciences | Patients with mild-to-moderate COVID-19 (age, >12 years)                  | Monoclonal antibody, binds to RBD of SARS-CoV-2 S protein | Risk reduction of hospitalization or death, 70%                              | (207)                    |
|                           | Vir Biotechnology, Inc.        | Monoclonal antibody, inhibits VEGF to suppress growth of new blood vessels | (trial no. NCT04545060)^a                          |                                                                               |                          |
| Regdanvimab (CT-P59)      | Celltrion                      | Patients with mild-to-moderate COVID-19                                    | Monoclonal antibody, binds to RBD of SARS-CoV-2 S protein | Potential                                                                    | (208)                    |
|                           |                                | Monoclonal antibody, binds to RBD of SARS-CoV-2 S protein                 | (trial no. NCT04525079, NCT04593641)^a            |                                                                               |                          |
| AZD7442                   | AstraZeneca plc                | Patients with mild-to-moderate COVID-19                                    | AZD1061 + AZD8895 monoclonal antibodies, binds two sites of SARS-CoV-2 S protein | Risk reduction of symptomatic COVID-19, 77% (trial no. NCT04625725)^a; risk reduction of hospitalization or death, 50%, (trial no. NCT04501978)^a | (165, 209)               |
|                           |                                | Monoclonal antibody, binds to RBD of SARS-CoV-2 S protein                 | (trial no. NCT04525079, NCT04593641)^a            |                                                                               |                          |
| BRII-196/BRII-198          | 02137.HK                       | Patients with mild-to-moderate COVID-19                                    | Monoclonal antibodies, binds two sites of SARS-CoV-2 S protein | Requires verification (trial no. NCT04501978)^a                             | (210)                    |
|                           |                                | Monoclonal antibodies, binds two sites of SARS-CoV-2 S protein            | (trial no. NCT04501978)^a                         |                                                                               |                          |
| DXP-593/DXP-604            | 688235.SH                      | Patients with mild-to-moderate COVID-19                                    | Monoclonal antibodies, binds two sites of SARS-CoV-2 S protein | Potential                                                                   | (136)                    |
|                           |                                | Monoclonal antibodies, binds two sites of SARS-CoV-2 S protein            | (trial no. NCT04501978)^a                         |                                                                               |                          |
| REGEN-COV (Ronaprev)       | Regeneron Pharmaceuticals, Inc., Roche | Patients with mild-to-moderate COVID-19                                    | Casirivima B + Imdevimab monoclonal antibodies, binds two sites of SARS-CoV-2 S protein | Risk reduction of symptomatic and asymptomatic COVID-19, 66.4% (NCT04452318)^a | (130, 211)               |
Table I. Continued.

B. Antibody-based therapy

| Name | Company | Indication | Mechanism of action | Effectiveness | (Refs.) |
|------|---------|------------|---------------------|---------------|---------|
| SARS-CoV-2 S protein | | | | risk reduction of hospitalization or death, 70-71% (trial no. NCT04425629)* |

*Primary endpoint of phase III study. N/A, not applicable; 3CL pro, 3-chymotrypsin-like protease; CYP3A4, recombinant cytochrome P450 3A4; S, spike; ACE2, angiotensin-converting enzyme 2; HSPGs, heparan sulfate proteoglycans; TMRSS2, transmembrane protease, serine 2; IMPDH, inosine monophosphate dehydrogenase; eEF1A, eukaryotic translation elongation factor 1; TLR, toll-like receptor; B cell, bone-marrow cell; RBD, receptor binding domain; VEGF, vascular endothelial growth factor.

Protease inhibitors lopinavir and ritonavir were the first drugs used in clinical trials to target Mpro/3CLpro (87), the primary protease of SARS-CoV-2 that inhibits activation of IFN-α pathway and facilitates natural immune escape and massive viral replication (88). Although lopinavir/ritonavir had no significant therapeutic effectiveness for patients with COVID-19, they are more effective when combined with other drugs such as ribavirin and interferon (89). Drugs to inhibit Mpro, such as GC-376, PF-07304814 and PF-07321332, are in different stages of clinical trials to confirm their effectiveness and practicability for application worldwide (90,91). Paxlovid, an oral drug combined with PF-07321332 and nirmatrelvir, was released by Pfizer, US in 2021; it has a significant effect against COVID-19 and is used to treat adults and children aged >12 years with mild/moderate disease, as well as those at high risk of transforming to severe cases (92). Chloroquine and hydroxychloroquine, antimalarial drugs, are potential but controversial drugs in COVID-19 treatment. Biological studies have proven the effect of hydroxychloroquine on controlling viral load but clinical trials have reported side effects and no significant therapeutic benefit (93,94). High-dose chloroquine for COVID-19 treatment is not recommended due to its toxic side effects, including increased levels of liver enzymes, corrected QT level prolongation and increased death rate (95,96).

Umifenovir (Arbidol) is a broad-spectrum antiviral drug for treatment of influenza that targets the interaction between S protein and ACE2; it has been shown to inhibit membrane fusion, thereby inhibiting virus diffusion into host cells (97,98). Clinical data show that it is more effective compared with lopinavir/ritonavir (89,99), although certain clinical trials have shown contrary results on patients with mild/moderate COVID-19 (100). GeLactoferrin targets heparan sulfate proteoglycans to prevent viral attachment to cells (101). Studies showed that lactoferrin combined with remdesivir has effects against COVID-19 (102,103), providing a basis further investigation in the treatment of clinical cases. Camostat mesylate, developed for treatment of pancreatitis, has been revealed to block virus entry into lung cells (104).

Inhibitors of viral RNA include remdesivir (GS-5734), favipivir (T-705), molnupiravir (MK-4482/EIDD-2801), AT-527, merimepobib and PTc299; their effectiveness for COVID-19 treatment requires investigation (105). Remdesivir, a broad-spectrum antiviral medicine developed for Ebola virus infection, is the first drug to be accepted for clinical trials of COVID-19 treatment (106). The effect of remdesivir is unknown and the high price and intravenous (IV) route of administration prevent its widespread use (107). Molnupiravir is the first orally available drug for COVID-19 that has broad-spectrum anti-RNA virus activity. Early use of molnupiravir for COVID-19 outpatients decreases risk of hospitalization or death (108). AT-527 is also an orally available drug which need further investigation for COVID-19 treatment (109).

By inhibiting host proteins that support viral RNA, drugs such as plitidepsin, fluvoxamine and ivermectin, may be potential treatments for COVID-19 (100). Based on biological studies and mouse experiments (110,111), plitidepsin may exert greater antiviral effects than remdesivir and its safety has been proven in a number of cancer clinical trials (112,113). Fluvoxamine, an antidepressant, was previously suggested to be associated with decreased plasma levels of certain inflammatory mediators and to prevent viral infection of epithelial cells (114). Whether ivermectin decreases risk of SARS-CoV-2 infection is still uncertain and needs further investigation (115).

Convalescent plasma (CP), a blood-derived product obtained from patients who have recovered from COVID-19, has been shown to limit viral expression and modify the inflammatory response (116). It has proven to be an effective COVID-19 treatment by randomized controlled trials and retrospective studies and high-titer CP may have a more significant effect compared with low-titer CP (117,118). It is more effective in severely or critically ill patients with rapid progression of illness (119). The rate of adverse events is low, but there is still the possibility of enhanced infection mediated by antibodies and acute lung damage or allergic reactions associated with transfusion (120).

High-dose intravenous immunoglobulin (IVIg) is a blood-derived product from patients who have recovered from COVID-19 and is used as a treatment for severely and critically
ill patients (121). Patients with ARDS or those on mechanical ventilation support may benefit from IVIG treatment. This therapy is usually not used alone but combined with other therapies, such as CP and antiviral drugs, to obtain greater clinical effect (122).

Monoclonal antibodies (mAbs) have been shown to neutralize COVID-19 infection both in vitro and in vivo (123,124). Despite the problems of bioavailability, high cost and limited supply using current technology, they may have wider clinical applications due to their ability of self-replicate, which CP does not possess (125). Severely ill patients commonly present with overexpression of IL-6 and cytokine storms in their serology profile; therefore, the inflammatory response may be alleviated by decreasing expression of IL-6 (126). Tocilizumab and sarilumab, high affinity antibodies for IL-6 receptor that are commonly used to treat arthritis and cytokine release syndrome, decrease the inflammatory response in COVID-19 (127). Tocilizumab was found to have no notable benefit for moderately ill patients in terms of decreased risk of transition to severe illness or death, while a multi-center study of critically ill patients revealed that early use of Tocilizumab may contribute to extended survival period (128). REGEN-COV, a mAb cocktails of neutralizing antibodies casirivimab and imdevimab, has an effect on preventing the aggravation of COVID-19 and decreases risk of hospitalization and death for patients with COVID-19 in high-risk groups (129). In addition, subcutaneous injection of REGEN-COV is effective for post-exposure prophylaxis (130).

Clinical trials have shown that REGEN-COV may have an antagonistic or synergistic action in combination with anti-inflammatory medications with diverse mechanisms of action; this requires further investigation (129). CT-P59, a fully human anti-SARS-CoV-2 mAb, has high binding affinity for RBD in S protein and prevents interaction with ACE2, which is key to prevent the virus from entering human cells (131). Experiments into the effect of sarilumab and bevacizumab on COVID-19 are ongoing (132,133). DXP-593 (based on SARS-CoV neutralizing mAb) had not meet the endpoint of validity on phase II trials and its action mechanism remains unknown (134,135).

Bamlanivimab (LY-CoV555/LY-CoV016, recombinant, fully human neutralizing IgG, mAb), sotrovimab (VIR-7831, fully human anti-SARS-CoV-2 mAb), REGN-10933, REGN-109876 and AZD1061 are effective against Omicron (136). In cell culture experiments, Omicron induces weaker neutralization by individual mAbs, thus contributing to immune escape (137-139). A trial investigating the effect of a panel of widely used mAbs against SARS-CoV-2 variants showed that combination of mAbs in low prophylactic doses is effective in preventing infection in mice (136), and high-dose REGEN-COV exhibits a notable therapeutic effect against Omicron infection (140). Although the mechanism SARS-CoV-2 variant immune escape remain uncertain, studies of mAbs indicate that identification of mAbs targeting highly conserved residues in viral S protein is key to avoid drug resistance and maintain effectiveness in treatment of COVID-19 variants (137,139). Nanobodies (alpaca-derived antibodies), miniproteins (artificially designed proteins), human soluble ACE2 and ACE2 receptor traps can inhibit S protein and have shown potential therapeutic effects; owing to their diverse biological mechanisms, their effectiveness in treatment needs to be confirmed by clinical trials (81).

Corticosteroids relieve the inflammatory response caused by infection via anti-inflammatory and immunoregulatory effects (141). However, studies have shown conflicting results regarding its clinical effects (142-144). For dexamethasone, certain studies have shown decreased death rate and notable benefits especially in severely or critically ill patients receiving invasive mechanical ventilation (145,146), while other studies showed higher death rate and multiple organ dysfunction (147,148). In consideration of rebound phenomena, withdrawal reaction and side effects of corticosteroid therapy, short-term use (3-7 days) is recommended to begin within ten days for patients exhibiting rapid disease progression (144). Attention should also be paid to the dose of corticosteroids; excessive dose may lengthen the time of viral elimination owing to its immunosuppressive effect and induce adverse effects (144).

Active measures, such as prevention and treatment for complications, treatment for primary illness, prevention of secondary infection and timely application of organ function support, which are therapeutic principles for severe and critical cases, are also required (81).

Severely ill patients with arterial O₂ partial pressure/fractional inspired O₂ levels <300 mmHg should be provided with oxygen therapy immediately and close observation is required following oxygen inhalation by nasal catheter or mask (149). If respiratory distress and/or hypoxemia do not improve within 1-2 h, high-flow nasal cannula oxygen therapy or non-invasive ventilation should be adopted. Invasive mechanical ventilation should be considered if hypoxemia does not improve within 1-2 h or occurs with excessive breathing and tidal volume (150).

Airway management is required to improve humidification of the airway and use of active heating humidifier and close sputum aspiration are recommended. To promote sputum drainage and lung rehabilitation, airway clearance treatment should be performed as early as possible while maintaining stable oxygenation and hemodynamics (151). Extracorporeal membrane oxygenation should be applied as soon as possible when meeting the indications and with no contraindication (152).

Critically ill patients can develop shock as a complication. Vasoactive medication should be used in addition to adequate fluid resuscitation. Changes in blood pressure, heart rate and urine volume, as well as lactic and alkaline residue, must be closely monitored, and hemodynamic monitoring should be performed to guide infusion and use of vasoactive drugs to promote tissue perfusion (149).

Severely and critically patients may be associated with a prothrombotic state, which increases risk of life-threatening venous thromboembolism (153). Therefore, prophylactic use of anticoagulant therapy is recommended for patients with significantly increased levels of D-dimer with no contraindications.

Critically ill patients who present with acute kidney damage may need continuous renal replacement therapy. The balance of water-electrolyte and acid-base must be closely monitored for adverse events such as hypoperfusion and medication (154).
Adsorption, perfusion, plasmapheresis, blood/plasma filtration and other blood purification systems remove inflammatory components and minimize the cytokine storm; these serve as an early or middle-stage therapy for cytokine storm in severe or critical cases (155).

For COVID-19 child patients with multisystem inflammatory syndrome, multidisciplinary cooperation of management is required; treatment for early inflammation, shock, coagulation dysfunction, organ failure and infection should be administered as necessary. Patients with COVID-19 with typical or atypical Kawasaki disease phenotypes are treated similarly to the classic treatment regimen for Kawasaki disease, with IVIgG, glucocorticoids and oral aspirin being the most common treatment (156). Intestinal microecological regulators maintain intestinal microecological balance and prevent secondary bacterial infection (157).

Traditional Chinese medicine (TCM) is used to treat and prevent infectious disease, including COVID-19. TCM therapies have shown therapeutic effects at every stage of the disease with wide application and no reported cases of exacerbation, even in the epidemic caused by Omicron (158). In China, TCM therapies such as decoction, patent medicine and acupuncture are used by >90% of the population (159).

In TCM, SARS-COV-2 is classified as ‘epidemic disease’ based on its transmission and clinical features. TCM divides the disease into medical observation and clinical treatment periods that are classified as four stages (mild, general, severe, critical) depending on the severity of disease. Numerous TCM principles and therapies are recommended in China and are usually combined with western therapies in clinical treatment to maximize therapeutic effect (160,161).

6. Measures to protect vulnerable groups: Vaccination

Vaccination may be the most effective method of overall long-term control of the novel coronavirus. Currently, development of effective vaccines is urgently required to decrease viral infection and provide protection for public health (162). A total of >100 vaccines have been developed based on a range of molecular platforms, such as DNA, mRNA in lipid nanoparticles, inactivated and live attenuated virus, protein subunits and recombinant vectors (163). A number of vaccines have exhibited good immunogenic effects in both clinical trials and real-world data (164,165). To March 2022, ten vaccines have exhibited good immunogenic effects in both clinical trials and recombinant vectors (163). A number of vaccines have also been investigated; S-Trimer (SCB-2019) (Janssen/Johnson & Johnson), Ad5-nCoV (CanSino Biologics) and live-attenuated Varicella Zoster vaccine has proven to exhibit the highest efficacy following full-course inoculation (173,174). A meta-analysis of real-world data (175) showed that the observed effectiveness of Pfizer/BioNTech was 91.2%, Moderna was 98.1% and CoronaVac vaccine was 65.7%. CoronaVac. AZD1222 mRNA vaccine also decreases the rate of severe infection caused by SARS-CoV variants.

Live-attenuated vaccines merit further investigation due to their low cost, strong immunogenicity and long-lasting immune effect. Δ3678 SARS-CoV-2, as a potential candidate for COVID-19 vaccine, has shown validity to a certain extent in mouse models (176). The Bacillus Calmette-Guérin vaccine has shown indirect protection against COVID-19 and live attenuated Varicella Zoster vaccine has proven to decrease risk of infection using multivariate logistic regression analysis (177). DNA vaccines include AZD1222/ChAdOx1 (Oxford/AstraZeneca), JNJ-78436735/Ad26.COV2.S (Janssen/Johnson & Johnson), Ad5-nCoV (CanSino Biologics) and ChAdOx1nCoV19 (Covishield) (166). Protein subunit vaccines have also been investigated; S-Trimer (SCB-2019) may be a candidate as it induces neutralizing antibody responses and has an acceptable safety assessment result (178). ZF2001, a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine, is well-tolerated and induced a good immune effect in phase I and II trials and may be a candidate protein subunit vaccine (179,180).

Adverse effects of vaccines can be considered to indicate antigenicity and immunogenicity, implying effective induction of immune responses, and severe adverse events caused by vaccination are rare (181).
effects such as fever, rash, weakness, nausea, vomiting, drowsiness, insomnia, pain and induration at injection site and lymphadenectasis similar to ordinary vaccines (182,183), the long-term side effects are unknown due to the short period of monitoring. People with strong immune responses may be susceptible to higher risk of autoimmune disease following vaccination, which is similar to other vaccines (184).

Adherence to hygiene guidelines is still required following vaccination because there is a delay between vaccination and optimal level of immunity; this differs between vaccines (185). Increased asymptomatic cases and emergence of variants increase risk of infection during development of vaccine-induced immunity, indicating the necessity of following hygiene guidelines (20).

Breakthrough infection of fully vaccinated people occurs in rapid spread of Omicron with high infectivity (186). Studies show that serum polyclonal antibody responses induced by vaccination or natural infection may be less effective against Omicron, which may account for immune failure and high levels of breakthrough infection with Omicron (187,188). Moreover, vaccine-induced protection decreases and while patients with breakthrough infections are more likely to have mild symptoms that do not require hospitalization compared with unvaccinated patients (189). Therefore, additional vaccine doses, changes in vaccine formulation or intervention should be adopted to when breakthrough infection cases increase, as well as further studying SARS-CoV-2 variants.

COVID-19 vaccines face challenges. Vaccines limit viremia and infection-associated syndromes via IgG response but do not involve IgA response in local mucosa, which is associated with virus transmission (163). Therefore, the possibility of transmission via droplets expelled from asymptomatic vaccinated patients cannot be ruled out and reinfection following vaccination is also a challenge (20,33). Global strategies are required for affordable global vaccination. Vaccine uptake presents a challenge owing to the poor public understanding and trust of vaccines and regional policies. Ethical and logistical considerations, such as clinical trials, distribution, prioritization, cultural, religious and political factors and regulation, are also challenges to achieving herd immunity (190).

7. Conclusion

To date, SARS-CoV-2 has been widespread in all regions with highly infectious Omicron variant posing a novel threat to global public health. Real-time guidance and epidemiological analysis should be shared to strengthen global cooperation against the epidemic. At present, the specific pathogenicity and response strategies of COVID-19 are uncertain, requiring further research.

Acknowledgements

Not applicable.

Funding

The present study was supported by The Traditional Chinese Medicine Science and Technology Development Plan Project of Shandong Province, China (grant no. 2019-0231).

Availability of data and materials

Not applicable.

Authors’ contributions

ZQ, CH and YC conceived and designed the review, ZQ, CH, JZ and YS wrote the manuscript. YS and JZ prepared the figures. LZ and YC performed the literature search. LZ and CH revised it critically for important intellectual content. All authors have read and approved the final manuscript. All authors are responsible for all aspects of the work and approve the submission in its current form. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497-506, 2020.
2. Scott L, Hisa NY, Moyo S, Singh L, Tegally H, Dor G, Maes P, Pybus OG, Kraemer MUG, Semenova E, et al.: Track omicron's spread with molecular data. Science 374: 1454-1455, 2021.
3. Dyer O: Covid-19: South Africa's surge in cases deepens alarm over omicron variant. BMJ 375: n3013, 2021.
4. Callaway E and Ledford H: How bad is Omicron? What scientists know so far. Nature 600: 197-199, 2021.
5. Giovanetti M, Benedetti F, Campisi G, Ciccozzi A, Fabris S, Ceccarelli G, Tambone V, Caruso A, Angeletti S, Zella D and Ciccozzi M: Evolution patterns of SARS-CoV-2: Snapshot on its genome variants. Biochem Biophys Res Commun 538: 88-91, 2021.
6. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L and Wang X: Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581: 215-220, 2020.
7. Chen Y, Liu Q and Guo D: Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol 92: 418-423, 2020.
8. Ke Z, Oton J, Qu K, Cortese M, Zila V, McKeane L, Nakane T, Zivanov J, Neufeldt CJ, Cerikan B and Lu JM: Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature 588: 498-502, 2020.
9. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS and Manson JJ; HLA Cross Speciality Collaboration, UK: COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 395: 1033-1034, 2020.
10. Thacker VV, Sharma K, Dhar N, Mancini GF, Sordet-Dessimoz J and McKinney JD: Rapid endothelitis and vascular damage characterize SARS-CoV-2 infection in a human lung-on-chip model. EMBO Rep 22: e52744, 2021.
11. Batah SS and Fabro AT: Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. Respir Med 176: 106239, 2021.
12. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, et al.: Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 315: 788-800, 2016.
13. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A; COVID-19 Genomics UK (COG-UK) Consortium, et al: SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 19: 409-424, 2021.
14. Bham L, Gao Q, Gao F, Wang Q, He Q, Wu X, Mao Q, Xu M and Liang Z: Impact of the delta variant on vaccine efficacy and response strategies. Expert Rev Vaccines 20: 1201-1209, 2021.
15. Sernberg A and Naujokat C: Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. Life Sci 257: 118056, 2020.
16. Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, et al: The omicron variant is highly resistant against antibody-neutralized neutralization. Implications for control of the COVID-19 pandemic. Cell 184: 455-464.e10, 2021.
17. Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, Kim BT and Kim SJ: Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol 30: 313-324, 2020.
18. Shehzadegan S, Alaghemand N, Fox M and Venketaraman V: Analysis of the delta variant B.1.617.2 COVID-19. Clin Infect 2021: 778-784, 2021.
19. Kannan SR, Spratt AB, Cohen AR, Naqvi SQ, Chand HS, Quinn TP, Lorson CL, Byrareddy SN and Singh K: Evolutionary analysis of the delta and delta plus variants of the SARS-CoV-2 virus. Lancet 124: 102715, 2021.
20. Chen J, Wang R, Gilby NB and Wei GW: Omicron variant (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. J Clin Infect Dis 62: 421-422, 2022.
21. Wang J, Yin XG, Wen Y, Lu J, Zhang RY, Zhou SH, Liao CM, Wei JW and Guo J: MPLA-adjutanted liposomes encapsulating S-trimer or RBD or S1, but not S-ECD, elicited robust neutralization against SARS-CoV-2 and variants of concern. J Med Chem 65: 3563-3574, 2022.
22. Meo SA, Meo AS, Al-Jassir SF and Klomoff DC: Omicron SARS-CoV-2 new variant: Global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci 25: 5015-5020, 2021.
23. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 395: 507-513, 2020.
24. Al-Shamsi HO, Alhazzani W, Althuraji A, Coomes EA, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, et al: A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: An international collaborative group. Oncologist 25: e936-e945, 2020.
25. Graselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cerda D, Coluccello A, Foti G, Fumagalli R, et al: Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 323: 1574-1581, 2020.
26. Halpin DMG, Faner R, Sibilia O, Badran R, Shams A, Roache C, et al: Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med 8: 436-438, 2020.
27. Luo C, Yao L, Zhang L, Yao M, Chen X, Wang Q and Shen H: Possible transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a public bath center in Huai'an, Jiangsu Province, China. JAMA Netw Open 3: e204583, 2020.
28. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, et al: A familial cluster of pneumonia associated with 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet 395: 514-523, 2020.
29. Kampf G, Todt D, Pfaender S and Steinmann E: Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 104: 246-251, 2020.
30. Atrezzoli CL, Makojia I, McCarthy RDP, Oldfield TM, Po J, Tang H, Stegmann FH and Clements TP: A guide to COVID-19: A global pandemic caused by the novel coronavirus SARS-CoV-2. FEBS J 287: 3633-3650, 2020.
31. Jayaweera M, Perera H, Gunawardana B and Manutunge J: Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. Environ Res 188: 105052, 2020.
32. Moraw ska L and Cao J: Airborne transmission of SARS-CoV-2: The world should face the reality. Environ Int 139: 105730, 2020.
33. Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S and Ma K: A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect 54: 12-16, 2021.
34. Pereira LJ, Pereira CV, Murata RM, Pardi V and Pereira-Dourado SM: Biological and social aspects of coronavirus disease 2019 (COVID-19) related to oral health. Braz Oral Res 34: e041, 2020.
35. Jackson CB, Farzan M, Chen B and Choe H: Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol 23: 3-20, 2022.
36. Meyerowitz EA, Richterman A, Gandhi RT and Sax PE: Transmission of SARS-CoV-2: A review of viral, host, and environmental factors. Ann Intern Med 174: 69-79, 2021.
37. Wild PS, Dimmeler S and Eschenhagen T: An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations. J Mol Cell Cardiol 141: 108-109, 2022.
38. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L and Wang M: Presumed asymptomatic carrier transmission of COVID-19. JAMA 323: 1406-1407, 2020.
39. Soetikno R, Teoh AYB, Kallenbach T, Lau JWY, Asokkumar R, Cabral-Prodigalidad P and Shergill A: Considerations in performing endoscopy during the COVID-19 pandemic. Gastroint Endosc 92: 176-183, 2020.
40. Ludwig S and Zarbock A: Coronaviruses and SARS-CoV-2: A brief overview. Anesth Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Analg Ana
55. Stang A, Robers J, Schonert B, Jöckel KH, Spelsberg A, Keil U, Auer H, Schommer J, Schmid R, and Safety of hydroxychloroquine chemoprophylaxis in SAR-CoV-2 infection: a randomized, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 8: 196-206, 2020.

56. Rahmani H, Davoudi-Monfared E, Nourian A, Khalili H, Jahizadeh N, Jalalabadi NZ, Fazeli MR, Ghazaemi A and Yekaninejad MS: Interferon-β-1b treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol 88: 106903, 2020.

57. Joseph BA, Dibus M, Evanson KW, Paranjape G, Vegivini CTR, Selvan PT, Sarasu K, Gupta N, Pulakurthy YS, Keesari PR, et al: Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review. Expert Rev Anti Infect Ther 19: 679-687, 2021.

58. Wu Y, Ma L, Zhang Z, Cai S, Zhao Z, Lou Z, Zhang J, Wang PH, Zhao J and Cui J: Main protease of SARS-CoV-2 serves as a bifunctional molecule in restricting type I interferon antiviral signaling. Signal Transduct Target Ther 5: 221, 2020.

59. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, et al: A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 382: 1787-1799, 2020.

60. Hu Y, Ma C, Szeto T, Hurst B, Tarbet B and Wang J: Boceprevir, capsaicin and calpain inhibitors II and X II, and Gc-376 have broad-spectrum antiviral activity against coronaviruses. ACS Infect Dis 7: 2833-2844, 2021.

61. Nish B, Jones RM, Anson BJ, Aresken D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H, et al: Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nat Commun 12: 6055, 2021.

62. Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, Zhou X, Wu Q, Zhang X, Feng Z, et al: Efficacy and safety of three new oral antiviral treatment (molnupiravir, favipiravir and Paxlovid) for COVID-19: A meta-analysis. Ann Med 54: 516-523, 2022.

63. Colson P, Rolain JM and Raoult D: Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents 55: 105923, 2021.

64. Cuadrado-Lavin A, Olmos JM, Cifrian JM, Gimenez T, Gandarillas MA, Garcia-Saiz M, Rebollo MH, Martinez-Taboada V, Lopez-Hoyos M, Fariñas MC and Crespo J: Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine and azithromycin in SARS-CoV-2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomized controlled trial. Trials 21: 472, 2020.

65. RECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emerson JR, Wiselka M, Lazarowski A, Elcock E, et al: Effect of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med 383: 2030-2040, 2020.
96. Gautret P, Lagier JC, Parola P, Hoang VT, Mejdoub L, Mailhe M, Doudier B, Courjon J, Giordano V, Vieira VE, et al: Hydroxychloroquine and azithromycin as a treatment of COVID-19: the AURORA open-label, non-randomized clinical trial. Int J Antimicrob Agents 56: 105940, 2020.

97. Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H, Li Y, Zhao L, Li W, Sun X, et al: The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov 6: 28, 2020.

98. Li H, Liu R, Zhang K, Zhang S, Wei Y, Zhang L, Zhou H and Yang C: Protective effect of arbidol against pulmonary fibrosis and sepsis in mice. Front Pharmacol 11: 607057, 2020.

99. Zhu Z, Lu Z, Xu T, Chen C, Yang Z, Zha T, Lu J and Xue Y: Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect 81: e21-e23, 2020.

100. Song Y, Zhao L, Wang K, Zhu M and Lu Y: COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). Int J Antimicrob Agents 56: 106080, 2020.

101. Wang B, Timilsena YP, Blanch E and Adhikari B: Lactoferrin: Structure, function, denaturation and digestion. Crit Rev Food Sci Nutr 59: 580-596, 2019.

102. Hu Y, Meng X, Zhang F, Xiang Y and Wang J: The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor. Emerg Microbes Infect 10: 317-330, 2021.

103. Salaris C, Scarpa M, Elli M, Bertolini A, Guglielmetti S, Pregliasco F, Blandizzi C, Brun P and Castagliuolo I: Protective antiviral activity of lactoferrin against SARS-CoV-2 infection in vitro. Nutrients 13: 328, 2021.

104. Hoffmann M, Klein-Weber H, Schroeder S, Krüger N, Herrler T, Erden MM, Fikrig E, Gugenheim S, Pregliasco F, Blandizzi C, Brun P and Castagliuolo I: Protective effects of lactoferrin against SARS-CoV-2 infection in vitro. J Infect Dis 213: 113201, 2021.

105. Cao W, Deng QX and Dai SX: Remdesivir for severe acute respiratory syndrome-CoV-2 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). Int J Antimicrob Agents 56: 106080, 2020.

106. Cao YC, Deng QX and Dai SX: Remdesivir for severe acute respiratory syndrome-CoV-2 causing COVID-19: An evaluation of the evidence. Travel Med Infect Dis 35: 101647, 2020.

107. Jackson LA, Anderson EJ, Roupahel NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al: An mRNA vaccine against SARS-CoV-2: preliminary report. N Engl J Med 383: 1920-1931, 2020.

108. Hansen H, Finne K, Disme G, Wang H, Kuttkner LD, Cheng A, Torring J, Nielson KL, Schwab F, et al: Treatment with convalescent plasma for COVID-19 infections: Results of a multicenter clinical study. Transfus Apher Sci 59: 617-623, 2020.

109. Chen S, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, et al: Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 323: 1582-1589, 2020.

110. Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, Wiggins CC, Senefeld JW, Klompas AM, Hodge DO, et al: Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc 95: 1888-1897, 2020.

111. Cao W, Liu X, Bai T, Fan H, Hong K, Song H, Han Y, Lin L, Ruan L and Li T: High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis 7: efoa102, 2020.

112. Cao W, Liu X, Hong K, Ma Z, Zhang Y, Lin L, Han Y, Xiong Y, Liu Z, Ruan L and Li T: High-dose intravenous immunoglobulin in severe coronavirus disease 2019: A multicenter retrospective study in China. Front Immunol 12: 627844, 2021.

113. Scialo F, Daniele A, Amato F, Pastore L, Matera MG, Cazzolla M, Castaldo G and Bianco A: ACE2: The major cell entry receptor for SARS-CoV-2. Lung 198: 867-877, 2020.

114. Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L, et al: A human neutralizing antibody targets the receptor-binding domain of SARS-CoV-2. Nature 584: 120-124, 2020.

115. Shepard HM, Phillips GL, D Thanos C and Feldmann M: Developments in therapy with monoclonal antibodies and related proteins. Clin Med (Lond) 17: 220-232, 2017.

116. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Xiao J, Hooper AT, Hamilton JD, Musser BJ, et al: REGEN-COV antibody combination and outcomes in outpatients with COVID-19. N Engl J Med 385: e81, 2021.

117. Khan FA, Stewart I, Fabbri L, Moss S, Robinson K, Smyth AR and Jenkins G: Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Ther Adv 16: 907-919, 2021.

118. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melemed ML, Beilenson JK, Leonberg-Yoo A, Schenck EJ, Radbel J, et al: Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med 181: 41-51, 2021.

119. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Xiao J, Hooper AT, Hamilton JD, Musser BJ, et al: REGEN-COV antibody combination and outcomes in outpatients with COVID-19. N Engl J Med 385: e81, 2021.

120. O'Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan KC, Sarkar N, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, et al: Subcutaneous REGN-COV antibody combination to prevent COVID-19. N Engl J Med 385: 1184-1195, 2021.

121. Ryu DK, Kang B, Noh H, Woo SJ, Lee MH, Nuijten PM, Kim JI, Seo JM, Kim C, Kim M, et al: The in vitro and in vivo efficacy of CT-P99 against delta, delta and its associated variants of SARS-CoV-2. Biochem Biophys Res Commun 537: 91-96, 2021.

122. Leschure FX, Honda H, Fowler RA, Lazar JS, Shi G, Wang P, Patel N and Hagedorn O: Sarilumab COVID-19 Global Study Group: Sarilumab in patients admitted to hospital with severe or critical COVID-19: A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 9: 523-532, 2021.

123. Pang J, Xu F, Dadieu G, Li Y, Fargalli A, Lu M, Valmadre G, Wei J, Bian Y, Canesi M, et al: Efficacy and tolerability of bevacizumab in patients with severe COVID-19. Nat Commun 12: 814, 2021.

124. Iucci M, Ferraro S, Contierto I, Cappello E, Valdiserra G, Blanchard C, Maggi F and Focosi D: Anti-SARS-CoV-2 neutralizing monoclonal antibodies: Clinical pipeline. MAbs 12: 185419, 2020.
135. Dejnirattisai W, Huo J, Zhou D, Zahradnik J, Supasa P, Liu C, Duyvesteyn HME, Gin HM, Mentzer AJ, Tukeprakhan A, et al: SARS-CoV-2 omicron-B.1.1.529 leads to widespread escape from neutralizing antibodies of neutralizing antibodies. Nature 620: 657-663, 2022.

137. Kakoulidis I, Ilias I and Koukkou E: SARS-CoV-2 infection.

140. Yuan M, Xu X, Xia D, Tao Z, Yin W, Tan W, Hu Y and Song C: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 620: 657-663, 2022.

141. Kakoulidis I, Ilias I and Koukkou E: SARS-CoV-2 infection.

142. Colby NL, Clark T, Raman R and Saiscekekar R: Insights on the neutralization landscape of the SARS-CoV-2 omicron variant. bioRxiv: doi: 10.1101/2021.12.06.471499 (Preprint).

143. Tang X, Feng YM, Xu JX, Zhang JY, Liu LM, Hu K, Wu XZ, Zhong JX, Chen JW, Zhang JC, et al: Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: A multicentre study. Clin Microbiol Infect 27: 105-111, 2021.

144. van Paassen J, Vos JS, Hoekstra EM, Neumann KMI, Boot PC and Aurbous SM: Corticosteroid use in COVID-19 patients: a retrospective cohort study. Intern Med 61: 1159-1168, 2022.

145. Ye R, Chen L, Huang X, Fan C, Xu J, Zhang H, Luan X, Zhao Y, Xu J, Yuan W and Chen H: Combating COVID-19 with integrated traditional Chinese and western medicine in China. Acta Pharm Sin B 2: 1149-1162, 2020.

146. Anad u, Jakhmola S, Indari o, Jha H, Luca c, Zhang JX, Chen JW, Zhang JC, et al: Efficacy of clonal antibody efficacy against SARS-CoV-2 variant strains. Immunol Lett 24: 241, 2020.

147. Rona Cor, Arzu A, Biccard BM, Aziati ID, Bricker TL, Joshi A, Neuman MD, Andruszkiewicz P, Baker PA, Bartello M, Marconi L, Scudeller L, Pancaldi L, Bartoletti M, Marconi L, Scudeller L, Pancaldi L, Darling TL, Ying B, Errico JM, Shrihari S, Owen D, Bern H, O’Hara J, McFarlane LR, Lemm NM, Higgs R, Cortes FH, Grifoni A, Tarke A, Chang J, et al: Efficacy of corticosteroid treatment for COVID-19 in the intensive care unit from the 2020 Hellenic Athens International Symposium. Anaesth Crit Care Med 39: 73-80, 2020.

148. Lenz S, Roginski MA, Montrief T, Ramzy M, Gottlieb M and Long B: Initial emergency department mechanical ventilation strategies for COVID-19 hypoxemic respiratory failure and ARDS. Am J Emerg Med 38: 2194-2202, 2020.

149. Wang D, Moghadam K, Owen R, Johnstone C, Neuman MD, Andruszkiewicz P, Baker PA, Biccard BM, Bryson GL, Chan MTV, et al: Emergency airway management in patients with COVID-19: A prospective international multicenter cohort study. Anesthesiology 135: 292-303, 2021.

150. Cook TM, El-Boghdady K, McGurie B, McNarry AF, Patel A and Higgs A: Consensus guidelines for managing the airway in patients with COVID-19: Guidelines from the difficult airway society, the association of anaesthetists the intensive care society, the faculty of intensive care medicine and the royal college of anaesthetists. Anaesthesia 76: 799-804, 2021.

151. Llitojoff JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M and Merouani K: High incidence of venous thromboembolic events in anticogulated severe COVID-19 patients. J Thromb Haemost 18: 1743-1746, 2020.

152. Ronco C, Bagshaw SM, Bellomo R, Clark WR, Husain-Syed F, Kellum JA, Ricci Z, Rimmele T, Reis T and Ostermann M: Extracorporeal blood purification and organ support in the critically ill patient during COVID-19 Pandemic: expert review and recommendation. Blood Purif 50: 17-27, 2021.

153. Kabeerdoss J, Pilakia RK, Karkhele R, Kumar TS, Danda D and Singh S: Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: Immunological mechanisms, clinical manifestations and management. Rheumatol Int 41: 19-32, 2021.

154. Mgeyri K, Dernovics Á, Al-Luabihi ZII and Rozsztóczy A: COVID-19-associated diarrhea. World J Gastroenterol 27: 3208-3222, 2021.

155. Zhu Y, Yang CL, Yang GG, Pan WX, Tian LG, Zheng JX, Lv S, Zhang SY, Zheng PY and Zhang SX: Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients: A randomized multicenter trial. Infect Dis Poverty 10: 31, 2021.

156. Zhao Z, Li Y, Zhou L, Zhou X, Xie B, Zhang W and Sun J: Prevention and treatment of COVID-19 using traditional Chinese medicine: A review. Phytomedicine 85: 153308, 2021.

157. Cook TM, El-Boghdady K, McGuire B, McNarry AF, Patel A and Medlock JM: Efficacy of corticosteroid treatment for COVID-19 in the intensive care unit: update in COVID-19 in the intensive care unit from the 2020 Hellenic Athens International Symposium. Anaesth Crit Care Med 39: 73-80, 2020.

158. Ronco C, Bagshaw SM, Bellomo R, Clark WR, Husain-Syed F, Kellum JA, Ricci Z, Rimmele T, Reis T and Ostermann M: Extracorporeal blood purification and organ support in the critically ill patient during COVID-19 Pandemic: expert review and recommendation. Blood Purif 50: 17-27, 2021.

159. Premikha M, Chiew CJ, Wei WE, Leo YS, Ong B, Lye DC, Lee YJ and Tan NC: Comparative effectiveness of mRNA and inactivated whole virus vaccines against COVID-19 infection and severe disease in Singapore. Clin Infect Dis: Apr 12, 2022 (Epub ahead of print).

160. Zhang Z, Mateus J, Coelho CH, Dan JM, Moderbaucher CR, Gilvez RI, Cortes-Franco A, Tarke A, Chai J, et al: Humoral and cellular immune memory to four COVID-19 vaccines. bioRxiv: doi: 10.1101/2022.03.18.484953 (Preprint).
174. Heilmann E, Costacurta F, Geley S, Mogadashi SA, Volland A, Rupp R, Harris RS and von Lauer D: A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition. Commun Biol 5: 391, 2022.

194. Mahase E: Covid-19; Covid-19: Pfizer's Paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ 375: n2713, 2021.

195. Nojomi M, Yassin Z, Keyvani H, Makiani MJ, Raham M, Laali A, Dehghan N, Navaei M and Ranbar: Method for capturing phenotypic effects of drugs. Mol Syst Biol 19: e1003953, 2022.

196. Udawadia ZF, Singh P, Barkate H, Patil S, Rangwala S, Pendse A, Kadam J, Wu W, Caracta CF and Tandon M: Remdesivir and safety of the mRNA-1273 SARS-CoV-2 vaccine candidate with accessory protein deletion. bioRxiv: 2022.04.14.480620, 2022.

208. Kim JY, Jang YR, Hong JH, Jung JG, Park JH, Streinu-Cercel A, Sabo T, Hall N, Foreman A, Schubert PL, Jung SM, Kim SH, et al: Early treatment with convalescent plasma therapies for the management of COVID-19. Blood 137: 1573-1581, 2021.

209. Schmidt F, Weisblum Y, Rutkowska M, Poston D, DaSilva J, Zhang F, Bednarski E, Cho A, Schafer-Babajev DJ, Ganger C, et al: High-throughput screening identifies two novel SARS-CoV-2 polyclonal neutralizing antibody escape. Nature 600: 512-516, 2021.

210. Case JB, Chen RE, Cao L, Ying B, Winkler ES, Johnson M, Guershink I, Pham MN, Shihari S, Kafai NM, et al: Ultraptent miniproteins targeting the SARS-CoV-2 receptor-binding domain in protect against infection and disease. Cell Host Microbe 29: 1151-1161.e5, 2021.

211. Guo K, Wustoni S, Koklu A, Diaz-Galicia E, Moser M, Hama A, Alqahtani AA, Ahmad AN, Alhamlan FS, Shuaib M, et al: Rapid single-molecule detection of COVID-19 and MERS antigens via nanobody-functionalized organic electrochemical transistors. Nat Biomed Eng 5: 666-677, 2021.

212. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandez AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM, et al: Efficacy of tocilizumab in patients hospitalized with COVID-19. N Engl J Med 384: 403-412, 2021.

213. Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, Sarkis E, Solis J, Zheng H, Scott N, et al: Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med 384: 413-422, 2021.

214. Chen P, Nirula A, H eller B, Gottlieb RL, Boscia J, Morris J, Huh G, Cardona J, Mo chera J, Blosor V, et al: Sarś-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. N Engl J Med 384: 229-237, 2021.

215. Kim JY, Jiang YR, Hong JH, Jung JG, Park JH, Streinu-Cercel A, Streinu-Cercel A, Sândulescu O, Lee SJ, Kim SH, et al: Safety, virological efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein: Two randomized, placebo-controlled, phase 1 studies in healthy individuals and patients with mild SARS-CoV-2 infection. Clin Ther 43: 1706-1727, 2021.

216. Levin MJ, Ustianowski A, De Wit S, Launoy A, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, et al: Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of COVID-19. N Engl J Med 385: 2188-2201, 2021.

217. ACTIV-3/3 Therapeutics for Inpatients with COVID-19 (TICO) Study Group: Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): A randomised controlled trial. Lancet Infect Dis 22: 1087-1101, 2021.